NYSE:DVADavita Stock Price, Forecast & News

Davita's stock was trading at $74.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DVA shares have increased by 8.3% and is now trading at $81.05. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Davita.

Davita is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Davita.

Davita Inc (NYSE:DVA) released its quarterly earnings results on Tuesday, May, 5th. The company reported $1.83 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.47 by $0.36. The business had revenue of $2.84 billion for the quarter, compared to analysts' expectations of $2.84 billion. Davita had a net margin of 7.85% and a return on equity of 32.45%. Davita's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the firm posted $0.91 earnings per share. View Davita's earnings history.

Davita issued an update on its FY20 earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of $5.75-6.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.01. The company issued revenue guidance of $11.5-11.7 billion, compared to the consensus revenue estimate of $11.65 billion.

11 brokerages have issued twelve-month price objectives for Davita's shares. Their forecasts range from $57.00 to $90.00. On average, they expect Davita's stock price to reach $68.86 in the next year. This suggests that the stock has a possible downside of 15.0%. View analysts' price targets for Davita.

Media stories about DVA stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Davita earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Davita.

Some companies that are related to Davita include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Davita investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), United Rentals (URI), AutoZone (AZO), Walt Disney (DIS) and Gilead Sciences (GILD).

Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DVA stock can currently be purchased for approximately $81.05.

Davita has a market capitalization of $9.87 billion and generates $11.39 billion in revenue each year. The company earns $810.98 million in net income (profit) each year or $5.40 on an earnings per share basis. Davita employs 65,000 workers across the globe.

The official website for Davita is www.davita.com.

Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected]